Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma. Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.
Study Type
OBSERVATIONAL
Enrollment
60
Overall Response Rate
Number of patients who achieve Complete Response or Partial Response after treatment
Time frame: End of front-line treatment (evaluated from diagnosis up to 30 months)
Progression Free Survival
Time from last response to nearest relapse or follow-up
Time frame: From first response to last follow-up for at least 2 years (up to 15 years)
Overall Survival
Time to last follow-up or death
Time frame: Date of last follow-up for at least 2 years (up to 15 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.